Scarica l'app Stockscreener
8.07
8.83%
0.655
Dopo l'orario di chiusura:
8.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$7.415
Aprire:
$7.75
Volume 24 ore:
28.87M
Relative Volume:
0.80
Capitalizzazione di mercato:
$8.30B
Reddito:
$113.29M
Utile/perdita netta:
$-351.47M
Rapporto P/E:
-20.70
EPS:
-0.3898
Flusso di cassa netto:
$-309.19M
1 W Prestazione:
-5.72%
1M Prestazione:
-15.41%
6M Prestazione:
+228.05%
1 anno Prestazione:
+194.53%
Intervallo 1D:
$7.45
$8.35
Intervallo di 1 settimana:
$6.54
$9.54
Portata 52W:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.07 | 7.62B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | BTIG Research | Buy |
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunitybio Inc Borsa (IBRX) Ultime notizie
Soon-Shiong’s Drug Deception - status.news
IBRX Stock Is Back: Anktiva Now Targets Severe Pneumonia After Clearing Key Checkpoint In Bladder Cancer Trial - Stocktwits
FDA Warning On Anktiva Puts ImmunityBio Growth Story Under Scrutiny - simplywall.st
ImmunityBio (NASDAQ:IBRX) Trading Up 8.9%Still a Buy? - MarketBeat
FDA Objects to Claims by Soon-Shiong on Cancer Drug - newser.com
FDA Issues Warning Letter to ImmunityBio | PharmExec - Pharmaceutical Executive
Why the FDA flagged ImmunityBio’s ‘false and misleading’ claims in podcast, TV spot - Medical Marketing and Media
ImmunityBio’s Global Expansion Raises Stock Speculation - timothysykes.com
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report? - Yahoo Finance
ImmunityBio Inc. (IBRX) Announces Approval for ANKTIVA® in Macau SAR, China - Yahoo Finance
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement - Pharmaceutical Executive
IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims - TradingView
IBRX stock still a buy after worst day in over a year? Why this analyst is shrugging off FDA warning letter - MSN
FDA warns manufacturer that billionaire's claims about cancer drug Anktiva are misleading - CBS News
Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX - The National Law Review
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
Kaplan Fox Investigating ImmunityBio for Potential Securities Violations - National Today
Kaplan Fox is Investigating ImmunityBio, Inc. (IBRX) for Potential Securities Law Violations - The National Law Review
FDA slams Soon-Shiong and ImmunityBio for making 'false and misleading' claims about a drug - statnews.com
FDA Issues Warning Letter to ImmunityBio Over 'False and Misleading' Claims for Bladder Cancer Drug Anktiva - drugscontrol.org
Drugmaker’s stock tumbles 20% after FDA issues formal warning to executives - HealthExec
Biopharma bites: ImmunityBio's 'misleading' ad, UCB's manufacturing hub, plus Aardvark's obesity pause - FirstWord Pharma
ImmunityBio (NASDAQ:IBRX) Trading Down 21.1%Time to Sell? - MarketBeat
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong - KIRO 7 News Seattle
Immunitybio Inc.Bio, News, Photos - Washington Times
Is ImmunityBio (IBRX) Still Attractive After A 365% Year To Date Surge - simplywall.st
Key facts: ImmunityBio $113M 2025 revenue; FDA questions ANKTIVA - TradingView
ImmunityBio Gains on Anktiva Approval in Macau, First in Asia | 2026News and Statistics - IndexBox
ImmunityBio Stock Falls on FDA Warning. No, Its Drug Can’t ‘Treat All Cancers.’ - Barron's
FDA Flags Misleading Claims on Cancer Drug Made by Billionaire Owner of ImmunityBio - MedPage Today
ImmunityBio stock price crash: buy the dip or sell the rip? - Invezz
Biotech Billionaire Gets FDA Warning Over Cancer Drug Claims - Fine Day 102.3
BTIG reiterates Immunitybio stock Buy rating after FDA warning By Investing.com - Investing.com Canada
Why ImmunityBio Stock Is Down More Than 20% Today - AOL.com
BTIG reiterates Immunitybio stock Buy rating after FDA warning - Investing.com
“FDA Warning” on Cancer Drug Sends ImmunityBio Stock (IBRX) Tumbling over 26% - TipRanks
ImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
ImmunityBio hit with FDA warning letter over Anktiva promotions in TV ad, podcast episode - Fierce Pharma
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy - Yahoo Finance
Promising Biotech Stocks Worth WatchingMarch 24th - MarketBeat
US FDA sends warning letter to ImmunityBio for "false or misleading" TV ad and podcast on Anktiva - marketscreener.com
ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad - TradingView
ImmunityBio initiates review after receiving FDA letter on Anktiva promotional materials - marketscreener.com
ImmunityBio Plunges After Getting FDA Warning on Cancer Drug Anktiva - Bloomberg.com
ImmunityBio Initiates Review After Receiving FDA Letter On ANKTIVA Promotional Materials - TradingView
FDA warns ImmunityBio over misleading podcast with Patrick Soon-Shiong - Endpoints News
Why ImmunityBio’s cancer drug claims alarmed the FDA - Rolling Out
ImmunityBio Faces Market Impact After Large Share Sale - StocksToTrade
ImmunityBio (IBRX) Shares Plunge 21% Following FDA Warning Letter on Misleading Cancer Drug Marketing - Blockonomi
ImmunityBio shares plunge after FDA warning over misleading ads - Investing.com
ImmunityBio (IBRX) Stock Drops 21% After FDA Says Its Cancer Drug Ads Broke the Law - CoinCentral
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):